Genomic Valley Biotech Limited has submitted its quarterly compliance certificate to BSE Limited pursuant to Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended March 31st, 2026. The certificate, dated April 14th, 2026, demonstrates the company's adherence to regulatory requirements governing depositories and participants.

Regulatory Compliance Filing

The certificate was filed by Managing Director Yogesh Agrawal with DIN 01165288, who digitally signed the document on April 14th, 2026. The submission was made to BSE Limited's Listing Department and Corporate Relationship Department at their Mumbai office.

Registrar Confirmation

Beetal Financial & Computer Services (P) Ltd, serving as the SEBI-approved Category I Registrar & Share Transfer Agent (Registration No. INR 000000262), provided comprehensive confirmation regarding dematerialization processes. The registrar confirmed that securities received from Depository Participants during the quarter ended March 2026 were properly processed and confirmed to the depositories.

Dematerialization Process Compliance

The registrar's certificate confirms several critical compliance aspects:

• Securities received for dematerialization were confirmed (accepted/rejected) to depositories
• All securities in the certificates have been listed on stock exchanges where previously issued securities are listed
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Depositories' names were substituted in the register of members as registered owners within the prescribed 15-day period

Company Information

Genomic Valley Biotech Limited operates from its registered office located at 4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil Bahadurgarh, District Jhajjar, Haryana. The company holds CIN L01122HR1994PLC033029 and maintains its corporate communications through established channels including email and website platforms.

This quarterly filing represents standard regulatory compliance for listed companies, ensuring transparency in share transfer and dematerialization processes as mandated by SEBI regulations.

Genomic valley biotech Limited has filed its annual regulatory declaration under SEBI's takeover regulations, confirming compliance with substantial acquisition norms for the financial year ended 31st March 2026. The declaration was submitted to BSE Limited and the company's audit committee as part of mandatory regulatory requirements.

SEBI Regulatory Declaration

Promoter Yogesh Agrawal filed the declaration under Regulation 31(4) of SEBI (Substantial Acquisition of shares & Takeover) Regulations, 2011 on 1st April, 2026. The declaration confirms that no encumbrance was made directly or indirectly during the financial year by the promoters, promoter group members, or persons acting in concert.

Company Information and Contact Details

Genomic Valley Biotech Limited operates from its registered address at 4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil Bahadurgarh, District Jhajjar, Haryana, India - 124 507. The company maintains corporate communication through genomicvalley@gmail.com and operates its website at www.genomicvalley.com .

Promoter Group Structure

The company's promoter group consists of three members across different categories as of March 31, 2026. The declaration was made on behalf of all promoters, promoter group members, and persons acting in concert with the company.

Regulatory Compliance

The declaration represents the company's adherence to SEBI's substantial acquisition and takeover regulations, which require periodic disclosures from promoters and associated entities. The filing confirms that no encumbrance activities occurred during the financial year, maintaining transparency in shareholding patterns and promoter activities. The document was digitally signed by Yogesh Agrawal and submitted to both BSE Limited and the company's audit committee as per regulatory requirements.